SCHEMBL6468962

SCHEMBL6468962

CC(CCc1ccc(N)nc1)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 4/20 0.48
KCNH2 Q12809 3/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
EGFR P00533 1/20 0.46
HTR2A P28223 2/20 0.45
HTR2B P41595 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
ADRA2C P18825 1/20 0.45
SLC6A4 P31645 1/20 0.45
ADRA1A P35348 1/20 0.45
DRD3 P35462 1/20 0.45
OPRK1 P41145 1/20 0.45
ROCK1 Q13464 1/20 0.44
HTR2C P28335 1/20 0.44
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042778 0.87 TMEM97 (0.63) TMEM97KCNH2MEN1KMT2AEGFR
SCHEMBL6471056 0.85 NOS1 (0.46) MEN1KMT2ACYP1A2CYP2D6CYP2C19
SCHEMBL6468961 0.84 VNN1 (0.53) TMEM97KCNH2MEN1KMT2AHTR2A
SCHEMBL5147202 0.83 MEN1 (0.45) TMEM97KCNH2MEN1KMT2ATP53
SCHEMBL5131617 0.82 BCHE (0.58) TMEM97KCNH2MEN1KMT2ASIGMAR1
SCHEMBL6470737 0.80 EGFR (0.43) TMEM97KCNH2MEN1KMT2AEGFR
SCHEMBL16363395 0.79 TMEM97 (0.55) TMEM97KCNH2MEN1KMT2AHTR2A
SCHEMBL6471113 0.78 TMEM97 (0.44) TMEM97KCNH2MEN1KMT2ALMNA
SCHEMBL14731710 0.78 TMEM97 (0.78) TMEM97KCNH2MEN1KMT2AHTR2A
SCHEMBL5037248 0.77 MEN1 (0.40) TMEM97KCNH2MEN1KMT2AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA TMEM97 2417/4885KCNH2 2412/4885MEN1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.